Special Issue "Skin Disorders in Hematological Disease"

A special issue of Healthcare (ISSN 2227-9032). This special issue belongs to the section "Environmental Factors and Global Health".

Deadline for manuscript submissions: 26 July 2021.

Special Issue Editors

Dr. Antonello Sica
Website
Guest Editor
Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
Interests: onco-hematological diseases; skin signs; histological and radiological features
Prof. Dr. Caterina Sagnelli

Guest Editor
Department of Mental Health and Public Medicine, Campania University Luigi Vanvitelli, Naples, Italy
Interests: Liver Diseases; Microbiology; Infectious Diseases; Liver Cirrhosis; HIV; Infectious Disease Medicine; Parasitology; Infectious Disease Epidemiology; Tropical Diseases

Special Issue Information

Dear Colleagues,

This Special Issue of Healthcare entitled “Skin Disorders in Hematological Disease” aims to collect and present data about the most recent developments in the field. We will welcome review and research articles, case reports, protocols, short communications, and interesting images. I propose for the purpose of scientific debate to also submit comments or replies about interesting observations published in Healthcare in 2020 or 2021, or about articles published in Special Issues, sent within 60 days of the online publication of the article of interest from this Special Issue.

This Special Issue will focus on the latest updates on the prevention, diagnosis, and treatment of skin disorders in hematological disease, aiming mainly to investigate how all these new developments are adjusted in clinical practice.

In this Special Issue, experts in this field will highlight the current approaches to the histopathological diagnosis and clinical management of patients with cutaneous signs of different subtypes of lymphoproliferative disorders, and of all other hematological diseases. Papers that exclusively represent histological and/or radiological profiles related to them are also welcome. Moreover, original articles will provide novel insight into the molecular pathogenesis and immunological hallmarks of cutaneous lymphoproliferative disorders which may be exploited for innovative treatment strategies in the future.

Dr. Antonello Sica
Prof. Dr. Caterina Sagnelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Skin disorders
  • Hematological disease
  • Lymphoproliferative disorders
  • Histological features
  • Radiological features
  • Immunosuppressed patients
  • Immunosuppressive therapies

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Other

Open AccessCase Report
Primary Extra-Nodal DLBCL of Glands: Our Experiences outside Guidelines of Treatment
Healthcare 2021, 9(3), 286; https://doi.org/10.3390/healthcare9030286 - 05 Mar 2021
Abstract
Lymphomas usually involve lymph nodes and other lymphoid tissues, but sometimes occur in non-lymphoid organs, called extra-nodal sites. Primary diffuse extra-lymph node large B-cell lymphoma (DLBCL) of the thyroid and parotid gland have been observed rarely. According to the most accredited guidelines, primary [...] Read more.
Lymphomas usually involve lymph nodes and other lymphoid tissues, but sometimes occur in non-lymphoid organs, called extra-nodal sites. Primary diffuse extra-lymph node large B-cell lymphoma (DLBCL) of the thyroid and parotid gland have been observed rarely. According to the most accredited guidelines, primary extra-nodal DLBCL of the parotid and thyroid glands should be treated with three cycles of R-CHOP followed by radiotherapy of the involved site (ISRT). Surgery alone is not enough to treat DLBCL. We describe two unusual cases of primary extra-nodal DLBCL in elderly patients treated exclusively with surgical resection, given the inability to apply chemotherapy. Both patients achieved clinical recovery, which was maintained after a follow-up of more than 18 months, despite not having performed the indicated chemotherapy protocol. The two cases presented here, and a few others reported in the literature, should be considered exceptions to the rule, and do not allow the conclusion that surgery alone might be sufficient for complete remission. Full article
(This article belongs to the Special Issue Skin Disorders in Hematological Disease)
Show Figures

Figure 1

Open AccessCase Report
How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report
Healthcare 2021, 9(2), 135; https://doi.org/10.3390/healthcare9020135 - 31 Jan 2021
Viewed by 326
Abstract
Background: The t (2; 5) chromosomal rearrangement of the ALK gene with nucleophosmin 1 gene (NPM1), resulting in an NPM1–ALK fusion, was first demonstrated in 1994 in anaplastic large cell lymphoma, (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in [...] Read more.
Background: The t (2; 5) chromosomal rearrangement of the ALK gene with nucleophosmin 1 gene (NPM1), resulting in an NPM1–ALK fusion, was first demonstrated in 1994 in anaplastic large cell lymphoma, (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab vedotin. These treatments are regarded as a bridge to allogeneic hematopoietic stem cell transplantation (allo-SCT). Nowadays, transplant procedures and the monitoring of chemotherapy patients proceed very slowly because the SARS-CoV-2 pandemic has heavily clogged the hospitals in all countries. Results: A 40-year-old Caucasian woman was first seen at our clinical center in June 2020. She had ALCL ALK+, a history of failure to two previous therapeutic lines and was in complete remission after 12 courses of brentuximab, still pending allo-SCT after two failed donor selections. Facing a new therapeutic failure, we requested and obtained authorization from the Italian drug regulatory agency to administer 250 mg of crizotinib twice a day, a drug incomprehensibly not registered for ALCL ALK +. Conclusions: The response to crizotinib was optimal since no adverse event occurred, and CT-PET scans persisted negative; this drug has proved to be a valid bridge to allo-SCT. Full article
(This article belongs to the Special Issue Skin Disorders in Hematological Disease)
Show Figures

Figure 1

Back to TopTop